YARMOUTH, Me. — Two forthcoming wearables for asthma detection will offer new options for patients and their care providers.
ADAMM from Healthcare Originals and the Fenom Home and Fenom Pro from Spirometrix are not yet cleared by the Food and Drug Administration, but they are already creating a stir in the market.
“The whole field of respiratory monitoring has been underserved,” said Jared Dwarika, co-founder of Healthcare Originals. “Many products are manufactured by trying to guess what the consumer wants and the patient won’t use it. We have asked the consumer what they wanted and built the product based on that feedback.”
Spirometrix CEO Dean Zikria added: “We want to disrupt the current standards through a unique technology and approach.”
ADAMM (Automated Device for Asthma Monitoring and Management) is a wearable patch that can stick to the front or back of the patient’s torso. It monitors for early breathing issues and sends an alert to a smartphone if action needs to be taken to prevent an attack. An accompanying app offers alerts and medication reminders.
The Fenom sensor-based devices measure the level of nitric oxide contained in a person’s breath, which, if high enough, could signal inflamed airways. The results are fed into a remote cloud-based database and combined with information from other connected devices, as well as data about the environment like pollen count, pollution index and air quality.
Dwarika believes that asthma patients become accustomed to their discomfort and learn to live with the suffering. He hopes the ADAMM will do more than monitor symptoms.
“Each time an asthmatic undergoes an asthma attack, he begins to accept a higher and higher threshold of symptoms before he reacts,” Dwarika said. “We’re hoping to raise self-awareness so the user will become aware of his condition earlier, giving him more time to react and get abatement for his symptoms sooner.”
Spirometrix expects clinical trials on the Fenom models to begin this fall in the U.S. The products recently received CE marking and should launch in some European countries in early 2017. The company will use distributors in most markets.
ADAMM is in the final stages of build-out, then it will go through the FDA clearance process. Dwarika said marketing will be tailored to the B2C and B2B markets.